About Atrial Fibrillation
According to the NHLBI of the NIH in the US, atrial fibrillation is one of the commonest type of arrhythmia. Atrial fibrillation is similar to another type of arrhythmia of the heart, superventricular tachycardia. The chief difference between these two types of arrhythmia is the consistency of the beats. In superventricular tachycardia, the heart beats are regular and at a very fast pace. Patients with atrial fibrillation experience fast and irregular heartbeats. In patients with atrial fibrillation, electrical signals travel rapidly in an uncontrolled way, which causes convulsion, palpitation or contraction in the atria of the heart. Blood is accumulated inside the atrial chambers, instead of flowing to the ventricular chambers. In this case, blood is not pumped into the ventricles fully. Also, the quantity of blood pumped out of the ventricles to the body is irregular and centered on the arbitrary atrial strokes. This can lead to the formation of blood clot in the atria. Stroke occurs in case the clot moves to the brain, which can cause death of an individual. In atrial fibrillation, the ventricles might beat for 100 to 175 times per minute, which is a stark contrast to the normal heart rate of 60 to 100 beats per minute. Atrial fibrillation is more common in older people and is detected using an ECG reading to find out the abnormalities of the electric signal. Some of the symptoms of atrial fibrillation are rapid and irregular heartbeat, palpitations, dizziness, sweating, chest pain, breathlessness, fatigue, and sometimes loss of consciousness.
According to the NHLBI of the NIH in the US, atrial fibrillation is one of the commonest type of arrhythmia. Atrial fibrillation is similar to another type of arrhythmia of the heart, superventricular tachycardia. The chief difference between these two types of arrhythmia is the consistency of the beats. In superventricular tachycardia, the heart beats are regular and at a very fast pace. Patients with atrial fibrillation experience fast and irregular heartbeats. In patients with atrial fibrillation, electrical signals travel rapidly in an uncontrolled way, which causes convulsion, palpitation or contraction in the atria of the heart. Blood is accumulated inside the atrial chambers, instead of flowing to the ventricular chambers. In this case, blood is not pumped into the ventricles fully. Also, the quantity of blood pumped out of the ventricles to the body is irregular and centered on the arbitrary atrial strokes. This can lead to the formation of blood clot in the atria. Stroke occurs in case the clot moves to the brain, which can cause death of an individual. In atrial fibrillation, the ventricles might beat for 100 to 175 times per minute, which is a stark contrast to the normal heart rate of 60 to 100 beats per minute. Atrial fibrillation is more common in older people and is detected using an ECG reading to find out the abnormalities of the electric signal. Some of the symptoms of atrial fibrillation are rapid and irregular heartbeat, palpitations, dizziness, sweating, chest pain, breathlessness, fatigue, and sometimes loss of consciousness.
TechNavio's analysts forecast the Global
Atrial Fibrillation market to grow at a CAGR of 11.05 percent over the period
2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Atrial Fibrillation market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs such as anti-arrythmics and anticoagulants used in the treatment of atrial fibrillation.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Atrial Fibrillation market. The vendor landscape section includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
This report covers the present scenario and the growth prospects of the Global Atrial Fibrillation market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs such as anti-arrythmics and anticoagulants used in the treatment of atrial fibrillation.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Atrial Fibrillation market. The vendor landscape section includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
TechNavio's report, Global Atrial
Fibrillation Market 2015-2019, has been prepared based on an in-depth market
analysis with inputs from industry experts. The report covers the Americas, and
the EMEA and APAC regions; it also covers the Global Atrial Fibrillation market
landscape and its growth prospects in the coming years. The report also
includes a discussion of the key vendors operating in this market.
Request
For Sample Report @ https://www.wiseguyreports.com/sample-request/38338-global-atrial-fibrillation-market-2015-2019
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Boehringer Ingelheim
• Janssen Pharmaceuticals
• Sanofi
• Americas
• APAC
• EMEA
Key Vendors
• Boehringer Ingelheim
• Janssen Pharmaceuticals
• Sanofi
Other Prominent Vendors
• ARCA Biopharma
• Armetheon
• Baxter
• Bristol-Myers Squibb
• ChanRx
• Daiichi Sankyo
• Gilead Sciences
• HUYA Biosciences
• Menarini
• Pfizer
• Pierre Fabre
• Servier
• Xention
• ARCA Biopharma
• Armetheon
• Baxter
• Bristol-Myers Squibb
• ChanRx
• Daiichi Sankyo
• Gilead Sciences
• HUYA Biosciences
• Menarini
• Pfizer
• Pierre Fabre
• Servier
• Xention
Market Driver
• Growing Patient Base
• For a full, detailed list, view our report
• Growing Patient Base
• For a full, detailed list, view our report
Market Challenge
• High Cost of Therapy
• For a full, detailed list, view our report
• High Cost of Therapy
• For a full, detailed list, view our report
Market Trend
• Shifting Focus on Emerging Markets
• For a full, detailed list, view our report
• Shifting Focus on Emerging Markets
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Complete
Report Details @ https://www.wiseguyreports.com/reports/38338-global-atrial-fibrillation-market-2015-2019
Table of Contents
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Pradaxa/ Prazaxa
04.1.2 Xarelto
04.1.3 Multaq
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Disease Overview
07.1 Understanding the Disease
07.2 Classification
07.3 Pathophysiology
07.4 Causes
07.5 Epidemiology
07.6 Management
07.7 Economic Burden
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis
09. Market Segmentation by Class of Drugs
09.1.1 Anticoagulants
09.1.2 Anti-arrythmics
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.2.1 Boehringer Ingelheim
18.2.2 Sanofi
18.2.3 Janssen Pharmaceuticals
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Boehringer Ingelheim
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Segmentation by Revenue 2013
19.1.4 Business Segmentation by Revenue 2012 and 2013
19.1.5 Geographical Segmentation by Revenue 2013
19.1.6 Business Strategy
19.1.7 Recent Developments
19.1.8 SWOT Analysis
19.2 Janssen Pharmaceuticals
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Recent Developments
19.2.4 SWOT Analysis
19.3 Sanofi
19.3.1 Key Facts
19.3.2 Business Description
19.3.3 Business Segmentation
19.3.4 Revenue by Business Segmentation
19.3.5 Revenue Comparison 2012 and 2013
19.3.6 Sales by Geography
19.3.7 Business Strategy
19.3.8 Key Developments
19.3.9 SWOT Analysis
20. Other Reports in this Series
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Pradaxa/ Prazaxa
04.1.2 Xarelto
04.1.3 Multaq
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Disease Overview
07.1 Understanding the Disease
07.2 Classification
07.3 Pathophysiology
07.4 Causes
07.5 Epidemiology
07.6 Management
07.7 Economic Burden
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis
09. Market Segmentation by Class of Drugs
09.1.1 Anticoagulants
09.1.2 Anti-arrythmics
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.2.1 Boehringer Ingelheim
18.2.2 Sanofi
18.2.3 Janssen Pharmaceuticals
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Boehringer Ingelheim
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Segmentation by Revenue 2013
19.1.4 Business Segmentation by Revenue 2012 and 2013
19.1.5 Geographical Segmentation by Revenue 2013
19.1.6 Business Strategy
19.1.7 Recent Developments
19.1.8 SWOT Analysis
19.2 Janssen Pharmaceuticals
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Recent Developments
19.2.4 SWOT Analysis
19.3 Sanofi
19.3.1 Key Facts
19.3.2 Business Description
19.3.3 Business Segmentation
19.3.4 Revenue by Business Segmentation
19.3.5 Revenue Comparison 2012 and 2013
19.3.6 Sales by Geography
19.3.7 Business Strategy
19.3.8 Key Developments
19.3.9 SWOT Analysis
20. Other Reports in this Series
Continued…….
CONTACT
US:
NORAH
TRENT
Partner
Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph:
+1-646-845-9349 (US)
Ph:
+44 208 133 9349 (UK)
No comments:
Post a Comment